Policy and Advocacy team
Works with governments, charities, commercial organisations and other funders to influence UK, EU and global policy developments.
We aim to influence policy developments so that researchers can be as effective as possible, and health can be improved.
We work with a wide range of partners – including governments, research funders, learned societies, charities and commercial organisations – in the UK, Europe and globally.
Ed Whiting
Director of Strategy
Natalie Paloma-Solis
Executive Assistant to Ed Whiting
Beth Thompson
Head of UK and EU Policy and Advocacy
Michelle Marshall
PA and Team Coordinator
Catherine Guinard
Policy and Advocacy Manager
Martin Smith
Policy and Advocacy Manager
Contact about: Brexit.
Natalie Banner
Policy and Advocacy Adviser (on secondment)
Contact about: data protection, patient data and medical records, Expert Advisory Group on Data Access, research ethics and governance.
Ben Bleasdale
Senior Policy and Advocacy Adviser
Contact about: UK research investment, funding structures, Research Excellence Framework, What’s it Worth studies.
Amelia Dearman
Policy and Advocacy Adviser
Contact about: immigration, innovation policy, All-Party Parliamentary Group on Medical Research, parliamentary communications, diversity, education and skills.
Simon Hall
Senior Policy and Advocacy Officer
Contact about: Brexit.
Sarah Rappaport
Policy and Advocacy Adviser
Contact about: emerging science and technologies, mitochondrial donation, regulation of clinical trials, research in the NHS, research involving embryos.
Alex Harris
Head of Global Policy and Advocacy
Contact about: COVID-19
Jack Snow
Team Coordinator
Contact about: general enquiries for Global Policy, cultural engagement.
Anna Lee
Policy and Advocacy Manager
Contact about: research uptake, COVID-19.
Will Hall
Policy and Advocacy Manager
Contact about: access to healthcare interventions (general), epidemic preparedness, sustainable development goals, COVID-19.
Olivia Allen
Policy and Advocacy Officer
Contact about: access to healthcare interventions (general), research uptake, COVID-19.
Heather Browett
Senior Policy and Advocacy Officer
Contact about: emerging science and technologies, research uptake, COVID-19.
Alice Jamieson
Policy and Advocacy Adviser
Contact about: epidemic preparedness, sustainable development goals, vaccines, WHO partnership, COVID-19.
Diogo Martins
Policy and Advocacy Officer (on secondment)
Contact about: snakebite, COVID-19.
Gemma Wardle
Policy and Advocacy Officer
Contact about: access to healthcare interventions, epidemic preparedness, COVID-19.
Will O’Leary
Policy and Advocacy Adviser
Contact about: research uptake, COVID-19.
Chloe Watson
Policy and Advocacy Adviser
Contact about: access to healthcare interventions, COVID-19.
Rachael Hore
Policy & Advocacy Officer
Contact about: access to healthcare interventions, COVID-19
We want to help the world overcome Covid-19. Research is the best way to save lives – but more investment in accessible treatments, tests and vaccines is urgently needed to change the course of the pandemic.
At least $8 billion of new funding is needed for the global response to COVID-19 – for research, development and supply of treatments for all, and support for public health measures in countries with the weakest health systems.
Current practices prioritise outputs over people’s wellbeing. We want to help build a better research culture – one that is creative, inclusive and honest.
How Wellcome is working to ensure that research evidence is used to influence policy and practice.
Research is an essential part of being ready for and responding to public health emergencies, like COVID-19 and Ebola.
Wellcome is working with the World Health Organization (WHO) to take on big challenges in global health
Randomised clinical trials are essential to advancing evidence-based medicine and improving human health. But new guidelines are needed, which is why we've launched the Good Clinical Trials Collaborative.
Everyone should have access to the life-changing benefits of medicines and other healthcare interventions, like vaccines, diagnostics and therapies.
We want the research we fund – like publications, data, software and materials – to be open and accessible, so it can have the greatest possible impact.
Knowledge and understanding don’t stop at borders. We're working with the UK government and others to achieve a Brexit settlement that allows research to thrive in the UK and Europe.
Emerging science and technologies, such as human genome editing and gene drive, could provide new solutions to health problems.
Patient data is hugely valuable for research. But the value of that data can only be unlocked if concerns about patient privacy are taken seriously.
We want to secure the investment in research promised by the UK government to overcome the biggest challenges in the world, such as climate change and epidemics.
The European General Data Protection Regulation was agreed in April 2016 and took effect from 25 May 2018.
The European Commission has published a proposal to update EU copyright law so that it applies equally across Europe and is fit for purpose in the 21st century.
Almost every major breakthrough in human and veterinary medicine has depended on the use of animals to research, develop or test new therapies.
Mitochondrial donation is an IVF technique that gives families affected by mitochondrial disease the chance of having healthy children.
The European Union is revising regulations governing the manufacture and sale of medical devices.
The Expert Advisory Group on Data Access promoted good working practices, consistent governance and transparent decision making for managing and using data from cohort studies.
The recommendations set out in the review mark one of the first steps towards making sure that promising drugs, devices, diagnostics and digital products are adopted quickly across the NHS.